Review anchor
Gamma-aminobutyric acid receptor subunit alpha-2
SINGLE PROTEIN · Rattus norvegicus
As of 2026-09-13
Evidence Snapshot
Gamma-aminobutyric acid receptor subunit alpha-2
CHEMBL341
SINGLE PROTEIN
Rattus norvegicus
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Gamma-aminobutyric acid receptor subunit alpha-2 as ChEMBL target CHEMBL341, mapped to UniProt P23576. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL341
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P23576
Gamma-aminobutyric acid receptor subunit alpha-2
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Gamma-aminobutyric acid receptor subunit alpha-2 matters
Gamma-aminobutyric acid receptor subunit alpha-2 is reviewed as Gamma-aminobutyric acid receptor subunit alpha-2 (UniProt P23576); the current evidence base includes 2 approved drugs, 76 compounds, and 15 assays, with lead potency reaching pChEMBL 7.9.
Protein context
Gamma-aminobutyric acid receptor subunit alpha-2
Gamma-aminobutyric acid receptor subunit alpha-2 Sequence length is 451 aa.
Review this target as Gamma-aminobutyric acid receptor subunit alpha-2, mapped to UniProt P23576. Sequence length is 451 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P23576
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 2 approved drugs, 76 compounds, and 15 assays for this target. The dominant activity type is KI. CHEMBL5272250 is the current potency anchor at pChEMBL 7.9.
Use CHEMBL5272250 as the tractability anchor when discussing potency (pChEMBL 7.9).
Activity source · ChEMBL 36 via Core Engine
2 approved
pChEMBL 7.9
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Gamma-aminobutyric acid receptor subunit alpha-2 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P23576, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
76
Total Compounds
15
Total Assays
2
Approved Drugs
IC50: 1.0, KI: 25.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL5272250
|
7.9 | Ki | — |
|
|
No preferred name
CHEMBL12
|
7.8 | Ki | Approved |
|
|
No preferred name
CHEMBL96
|
7.7 | IC50 | — |
|
|
No preferred name
CHEMBL521901
|
7.1 | Ki | — |
|
|
No preferred name
CHEMBL127135
|
6.9 | Ki | — |
Source Header